Tweetchat on RNA Interference Upstages iPhone (Not Really, but It Was Still Fun)
Summary
Alnylam Pharmaceuticals CEO John Maraganore had a zinger ready yesterday as Apple’s dog-and-pony show was happening during the first Xconomy “Tweetchat,” on the latest ups and downs in RNA interference.@adamfeuerstein (Adam Feuerstein, Sr. columnist for the TheStreet) @biotechcfo (Daniel Davis, director life sciences & technology at AMS) @Chris_Evelo (Chris Evelo, Head of the Department of Bioinformatics – BiGCaT at Maastricht University in the Netherlands) @JohnCFierce (John Carroll, editor in chief, FierceBiotech) @bio1x1 (Bio 1×1 Partnering, based in Washington DC) @corytromblee (Cory Tromblee, life sciences communications pro) @JohnJSeng (John Seng, founder and president of Spectrum) @tweetingbiotech (Jennifer Conrad, Sr. account executive at MacDougall Biomedical Communications) @scientre (Laura Strong, president of Madison, WI-based Quintessence Biosciences) @illuminatethis (Amber Harloff) @outlinescience (Mawethu Bilibana, Blogger, Professional student (PhD Chemistry) at UWC and NGO non-executive in Cape Town, South Africa) @sjohnson7808 (Steve Johnson) @claytoncomm (Cynthia Clayton, communications, Alnylam) @biotechben (Benjamin Navon, Biotech, life sciences, and healthcare PR pro) @bioduediligence (PhD scientist and biotechnology stock investor) @IBT_Bioservices (IBT Bioservices is a collaborative research organization offering R&D services to identify vaccines and therapeutics with anti-infective activity) @roseanneseguin (Montreal, Quebec) @bradloncar (Private investor) @Michael_Gilman (Scientist and entrepreneur.Founder/CEO of @Stromedix) @alalejandro (Adriana Alejandro, scientific consultant) @LifeSciVC (Bruce Booth, early stage VC, recovering scientist) @brownerM9 (Michelle Browner, CEO of Enlight Biosciences) @microryza (Fun Guy) @MelissaLerch (Melissa Lerch, Scientist passionate about global health, infectious disease, science communication, travel, and life) @Robert_Overell (Robert Overell, CEO of PhaseRx) @kevinccc (Kevin Colwill, individual biotech investor) There were lots of good questions, and amazingly, Maraganore was able to keep up and answer all of them as far as I could tell.From @scientre “Will clinical POC need to be in disease where delivery very general (beyond eye, liver) before skeptics get on board?” Maraganore’s answer: “re: clinical POC; liver is huge win for field & creates opportunities 4 lots of meaningful drugs.” From @sjohnson7808 “Reasons/causes of liposome induced inflammation been figured out?” The response from Alnylam’s CEO: “re: liposome inflammation; high doses >1mg/kg are pro-inflammatory.Afterward, he said in an e-mail, “It was fun for sure!” If you have other suggestions of interesting life sciences topics and speakers that we might want to put together for future Tweetchats, just send me a note via e-mail.
Classifications
AskAI Classifications
LabelsLinked Companies
